Julia Dilliard
Rheumatology · Dallas, TXNPI 1184844268
Payments from drug & device makers
Across 193 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Lilly USA, LLC$465
- Novo Nordisk$412
- Sanofi-aventis U.S. LLC$404
- AstraZeneca$372
- Mannkind Corporation$329
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,21599%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $1,115 |
| Lilly USA, LLC | 27 | $465 |
| Novo Nordisk | 16 | $412 |
| Sanofi-aventis U.S. LLC | 12 | $404 |
| AstraZeneca | 11 | $372 |
| Mannkind Corporation | 15 | $329 |
| Dexcom, Inc. | 8 | $212 |
| Tandem Diabetes Care, Inc. | 4 | $189 |
| Cequr Corporation | 4 | $174 |
| Xeris Pharmaceuticals, Inc. | 8 | $170 |
| Medtronic | 8 | $147 |
| Amgen | 8 | $141 |
| Radius Health, Inc. | 6 | $137 |
| Boehringer Ingelheim | 6 | $136 |
| Insulet Corporation | 7 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $95 |
| Neurocrine Biosciences, Inc. | 3 | $93 |
| Corcept Therapeutics | 3 | $69 |
| AbbVie | 3 | $62 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| IBSA Pharma Inc. | 3 | $50 |
| Sequel Med Tech, LLC | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Alvogen Inc | 2 | $42 |
| Avvisto Therapeutics, LLC | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Nevro Corp. | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$429
- FARXIGA$221
- FreeStyle Libre$178
- FreeStyle Libre 2$145
- TZIELD$128
- Ozempic$115
- t:slim X2 Insulin Pump with Control-IQ$107
How this compares
$5,274 in reported general payments places this provider in the 45th percentile of 512 rheumatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 233 | $419,320 |
| MounjaroTirzepatide | 135 | $213,446 |
| JardianceEmpagliflozin | 151 | $201,582 |
| TrulicityDulaglutide | 55 | $90,760 |
| FarxigaDapagliflozin Propanediol | 44 | $57,667 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $57,201 |
| JanuviaSitagliptin Phosphate | 41 | $53,769 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $51,929 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $50,578 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $49,740 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $43,317 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $41,562 |
| RybelsusSemaglutide | 26 | $39,871 |
| Humalog Kwikpen U-100Insulin Lispro | 86 | $32,332 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $29,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $412 | $481,318293 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $465 | $324,467259 claims |
| Boehringer IngelheimJardiance, Tradjenta | $136 | $230,922176 claims |
| AstraZenecaFarxiga | $372 | $57,66744 claims |
| AbbVieSynthroid | $62 | $4,42641 claims |
| Sanofi-aventis U.S. LLCLantus | $404 | $2,98124 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $1,865157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Dallas
- John CushDallas$3.9M
- Stanley CohenDallas$1.9M
- David KarpDallas$788K
- Sharad LakhanpalDallas$718K
- Margarita FallenaDallas$488K
- Zoran KurepaDallas$483K
- Dianne PetroneDallas$437K
- Giovanni GeslaniDallas$415K
- Kathryn DaoDallas$381K
- Pedro CastilloDallas$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.